Characteristics of severe asthma patients included in the French Palomb Cohort
| العنوان: | Characteristics of severe asthma patients included in the French Palomb Cohort |
|---|---|
| المؤلفون: | JESTIN-GUYON, Nolwenn, OUAALAYA, El Hassane, OZIER, Annaig, NOCENT, Cecilia, BERNADY, Alain, NGUYEN, Laurent, BERTEAUD, Emilie, DUPUY-GRASSET, Magali, LE GUILLOU, Frederic, MELLONI, Boris, PORTEL, Laurent, PRUD'HOMME, Anne, DIDIER, Alain, MOLIMARD, Mathieu, GUILLEMINAULT, Laurent, RAHERISON-SEMJEN, Chantal |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Asthma management, Environment, Severe asthma, Sciences du Vivant [q-bio]/Santé publique et épidémiologie |
| الوصف: | Background: The prevalence of severe asthma among asthmatic patients is estimated between 5-10% in France. The aim of this work was to describe clinical features of patients included in the French Severe Asthma Palomb cohort. Methods: Patients followed in a real-life context by pulmonologists located in 2 regions since 2019. Inclusion criteria: 1) ⩾18 years-old, 2) >6 months follow-up before inclusion for severe asthma, (GINA, 2019) 3) combination of ICS and LABA and anticholinergic, associated with 4) OCS, anti-IgE based treatment, anti-IL5, anti-RIL5, anti-IL4, anti-IL13, thermoplasty. Results: In January 2023, 214 patients were included. Mean age was 55.1 years old (±16.4). 61.7% were female, 30.0% had a BMI⩾30 (morbid/severe obesity), 29.3% were previous smokers and 4.8% current smokers. 61.4% had an onset of asthma symptoms after the age of 15 and 21.8% had a history of acute severe asthma. 36.8% had dyspnea (mMRC⩾2) and 23.8% had chronic cough (>8 weeks). During the 12 months before inclusion, 25.2% had at least 2 exacerbations (having required a general corticotherapy or an increase in ICS treatment). 29.0% had chronic rhinitis, 22.9% gastro-esophageal reflux disease, 19.2% chronic rhinosinusitis, 14.0% anxiety, 13.6% blood hypertension and 13.1% sleep apnea syndrome. Regarding phenotypes: 46.0% were eosinophilic with allergy and 32.1% were eosinophilic without allergy. 135 patients were already on a biotherapy treatment at inclusion and 26 had a biotherapy introduced at inclusion. Conclusion: These are preliminary results of an observatory of patients followed with severe asthma in the French medical framework. Sponsors: Bordeaux University Foundation, AstraZeneca, Chiesi, GSK, Novartis, Sanofi. |
| نوع الوثيقة: | other/unknown material |
| اللغة: | English |
| تدمد: | 0903-1936 |
| Relation: | https://oskar-bordeaux.fr/handle/20.500.12278/188162 |
| DOI: | 10.1183/13993003.congress-2023.PA4432 |
| الاتاحة: | https://oskar-bordeaux.fr/handle/20.500.12278/188162 https://hdl.handle.net/20.500.12278/188162 https://doi.org/10.1183/13993003.congress-2023.PA4432 |
| Rights: | open ; Pas de Licence CC |
| رقم الانضمام: | edsbas.4E98CE1E |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 09031936 |
|---|---|
| DOI: | 10.1183/13993003.congress-2023.PA4432 |